Wardwizard Healthcare appointed Ms. Sathi Kundu as Additional Independent Woman Director and approved Mr. Yuvraj Priyadarshi’s elevation to Whole Time Director at its board meeting on August 31, 2026.

The appointments were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, following recommendations from the Nomination and Remuneration Committee.

Board Appointments

Ms. Kundu, who holds a Bachelor of Arts and a Bachelor of Law from the University of Calcutta, brings over 15 years of legal experience. Her appointment as an Additional Independent Woman Director is effective immediately for a five-year term, subject to shareholder approval at the ensuing general meeting.

Mr. Priyadarshi, currently serving as CEO since November 14, 2025, and appointed as an Additional Director in March 2026, will assume the role of Whole Time Director starting September 30, 2026. This appointment is also subject to shareholder approval.

Director Profiles

Mr. Priyadarshi holds a Doctor of Optometry, Master of Science in Vision Science, and an MBA in Hospital Management. His professional background includes nine years with the World Health Organization in East Africa and two years as COO of Mombasa Eye Hospital.

Both directors have confirmed no relationships with other board members and no debarment by SEBI or other authorities.

Wardwizard Healthcare approved a preferential issue of up to 1,25,00,000 fully convertible warrants worth ₹12.5 crore during its board meeting on August 31, 2026. The company also increased its authorized share capital from ₹7.5 crore to ₹25 crore.

The board sanctioned the issuance at ₹10 per warrant, determined in accordance with Chapter V of SEBI (ICDR) Regulations, 2018. Each warrant is convertible into one equity share of ₹10 face value within 18 months of allotment. Unconverted warrants will lapse, and the amount paid will be forfeited. Proceeds will fund growth initiatives, working capital, and investments in group entities such as Wardwizard Medicare Private Limited.

Capital Structure Changes

The authorized capital increase allows the company to issue up to 2.5 crore equity shares of ₹10 face value each, replacing the previous limit of 75 lakh shares. The new shares rank pari-passu with existing equity.

Promoter and Investor Participation

Promoters Yatin Sanjay Gupte and Sheetal Mandar Bhalerao are among the proposed allottees. Gupte holds 37.04% of pre-issue shares (90,750 shares) and is allotted 52,00,000 warrants. Post-conversion, his stake would rise to 41.51%. Bhalerao holds 14.19% (34,760 shares) and receives 18,00,000 warrants, bringing his post-conversion holding to 14.40%.

Non-promoter allottees include Ram Chander Sharma, Nitu Sharma, Ram Chander Sharma HUF, Shyam Sunder Sharma, Hemlata Sharma, Shyam Sunder Sharma HUF, Aakanksha Kabra, Ilyashbhai Dhobi, Sanjay Kumar Sharma, Pooja Chotia, Havish Suppliers LLP, Kailash Dhanuka HUF, Ruchika Dhanuka, Arpit Kabra, P. B. Films Limited, and Kyan Investment & Trading Company Private Limited. No single non-promoter entity exceeds a 4.94% post-conversion stake.

Board Appointments

Ms. Sathi Kundu was appointed as an additional independent director for a five-year term effective August 31, 2026. She brings over 15 years of legal experience. Her appointment requires shareholder approval at the upcoming annual general meeting.

Mr. Yuvraj Priyadarshi was appointed as whole-time director effective September 30, 2026. He previously served as CEO since November 14, 2025. His five-year term is subject to shareholder ratification.

Annual General Meeting

The 42nd AGM is scheduled for September 30, 2026, via video conferencing. Remote e-voting will run from September 27 to September 29, 2026. The register of members remains closed from September 23 to September 30, 2026.